GLU24/7 study: cardiometabolic health risk factors in night shift workers - protocol for a 2-year longitudinal study in an industrial setting in Norway.

Abstract

Evidence links night shift work to circadian rhythm disruption, causing hormonal and metabolic alterations, as well as increased risk for cardiovascular disease (CVD). This study investigates whether night shift work affects blood glucose variability and dysregulation, potentially driven by circadian misalignment. It also examines whether such disruptions elevate inflammatory markers involved in atherosclerosis and contribute to the exacerbation of CVD risk markers. The study includes 60 participants: rotating night shift workers (day, evening, and night shifts) and day workers (controls) at a pharmaceutical plant. We will assess the effects of night shift work on metabolic and cardiovascular health over three phases: an initial 6-week observational period (phase I), baseline registration of CVD risk factors (phase II), and follow-up assessment of CVD risk factors at 2 years (phase III). Phase I registrations include working hours derived from payroll data, sleep metrics by OURA ring (actigraphy, plethysmography and temperature), continuous assessments of blood glucose using continuous glucose monitor, self-reported food diary and measurements of circadian rhythm markers (monocyte mRNA expression). In phases II and III, blood CVD risk factors such as markers of inflammation, lipids, glycosylated haemoglobin, D-dimer, clinical examination of blood pressure, resting heart rate, arterial stiffness by the means of carotid to femoral pulse wave velocity, carotid intima-media thickness and maximal oxygen uptake (V̇O_2max) are measured. To this end, a comprehensive set of methods will be used in a prospective manner to provide new knowledge on shift work-induced glucose regulation and CVD risk factors. All participants provided written informed consent prior to participating in the study, which will adhere to the principles outlined in the Declaration of Helsinki. Ethical approval has been granted by the Norwegian Regional Committee for Medical Research Ethics South-East B (reference # 745702). Dissemination plans include academic and public publications, as well as collaborations with national and regional policy-makers.